Estrogen receptor alpha gene variant, PvuII (rs2234693), as a potential pharmacogenetic biomarker for aneurysmal subarachnoid hemorrhage in postmenopausal women

Biomarkers in aneurysmal subarachnoid hemorrhage: A short review

“…Ramesh et al found that postmenopausal women with low-estradiol levels and with the TT genotype of PvuII variant in the ESR1 gene are at 3.5- folds higher risk of aSAH (CI 95% 1.424–8.828, p = 0.0074). 47 Crago et al provided the first clinical evidence that plasma E1 and E2 concentrations are associated with the severity of injury and outcomes after aSAH. Higher E1 and E2 levels were associated with higher Hunt-Hess grade (E1, p ¼ 0.01; E2, p ¼ 0.03), the presence of DCI (E1, p ¼ 0.02; E2, p ¼ 0.02), and poor 3-month outcomes (E1, p ¼ 0.002; E2, p ¼ 0.002).…”